Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Percheron Therapeutics ( (AU:PER) ) has shared an announcement.
Percheron Therapeutics Limited has announced a non-renounceable pro-rata bonus offer of Loyalty Options to its eligible shareholders, providing them with an opportunity to participate in the company’s future success. However, the offer is limited to shareholders with registered addresses in Australia, New Zealand, Singapore, and Hong Kong, excluding those in other jurisdictions due to regulatory and cost considerations.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a company operating in the biotechnology industry, focusing on developing therapeutic solutions. The company is listed on the Australian Securities Exchange (ASX:PER) and is committed to engaging its shareholders through various incentive programs.
Average Trading Volume: 4,356,555
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
For an in-depth examination of PER stock, go to TipRanks’ Stock Analysis page.